Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Katsuhiro, Ishida, Mitsuaki, Yanai, Hirotsugu, Tsuta, Koji, Sekimoto, Mitsugu, Sugie, Tomoharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462691/
https://www.ncbi.nlm.nih.gov/pubmed/34559865
http://dx.doi.org/10.1371/journal.pone.0257860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462691/
https://www.ncbi.nlm.nih.gov/pubmed/34559865
http://dx.doi.org/10.1371/journal.pone.0257860

Ejemplares similares